Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.

Braveheart Bio

Travis Murdoch

This department focuses on the strategic integration of clinical and medical insights to support product development and regulatory processes.

Medical Affairs

This department oversees the strategic direction and governance of the organization through its board members.

Board Governance

This department is responsible for managing the company's financial planning, reporting, and accounting functions.

Finance Department

This department focuses on strategic planning, partnerships, and human resources management to enhance organizational growth and effectiveness.

Corporate Development

This department specializes in the analysis and interpretation of biological data and oversees the development of pharmacological and drug metabolism processes.

Biometrics and Pharmacology

This department oversees the planning, execution, and management of clinical trials to ensure compliance and efficiency.

Braveheart Bio

Org chart

Teams

Medical Affairs

Board Governance

Finance Department

Corporate Development

Biometrics and Pharmacology

Clinical Operations

Offices

Braveheart Bio

Org chart

Teams

Medical Affairs

Board Governance

Finance Department

Corporate Development

Biometrics and Pharmacology

Clinical Operations

Offices

Related companies